The Senate passed a bill on March 14 that would reclassify fentanyl as a Schedule I narcotic, pulling it from medical use and toughening penalties for those charged with criminal offenses related to the drug.
The HALT Fentanyl Act categorizes any fentanyl-related substances, which include any chemical or compound that is structurally or molecularly related to the highly addictive synthetic opioid, as a Schedule I drug under the Controlled Substances Act.
Schedule I drugs, such as heroin, ecstasy, and LSD, are substances that are deemed to have no medical use and can be subject to a high abuse potential.
There are five scheduling categories under the Controlled Substances Act, with the lowest having the smallest potential for abuse, including certain cough medications.
Schedule I substances also come with steeper criminal penalties, with those convicted of such offenses sometimes getting up to 40 years in prison on a first offense, or more if deaths or serious injuries are involved.
While the legislation allows for fentanyl research to continue by relevant federal agencies and institutions receiving funding from the Departments of Health and Human Services, Defense, and Veterans Affairs, there are restrictions.
Before beginning fentanyl-related studies, researchers must wait 30 days after notifying the Justice Department and disclosing research information, including the substance’s chemical name and how much will be used in the study.
Fentanyl has been in the spotlight for years due to the U.S. opioid crisis and numerous drug trafficking incidents at the southern border.
When Trump imposed 25 percent tariffs on Mexico and Canada and 20 percent tariffs on China earlier this month, he blamed the countries for failing to stop fentanyl trafficking into the United States.
Mexico and Canada have since taken steps to tighten their border control.